In this episode, guest Brett King, MD, PhD, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata and conversations with patients surrounding medical pauses. •    Intro 0:29 •    Brett King, MD, PhD 0:41 •    When a patient comes to the office with alopecia areata and want to go on a JAK inhibitor, how do you counsel them about their likelihood for significant hair regrowth?  1:35 •    Is your estimate of roughly fifty percent rate from data, or from your own experiences with patients?  6:03 •    How do you explain boxed warnings to patients using or thinking about using JAK inhibitors? 8:29 •    Gelfand and King on the challenges presented by the current data on alopecia areata patients using JAK inhibitors.  12:02 •    Is it true that patients experience hair loss quickly after going off JAK inhibitors? 12:49 •    How do you manage these challenges in real-world clinical practice?  13:40 •    With JAK, how do you deal with the issue of non-follow-up patients?  17:42 •    Thank you, Dr. King. 19:55 Brett King, MD, PhD, is an associate professor of dermatology at Yale School of Medicine.

We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn. King can be reached on X @Brett_King_ and on LinkedIn.

For more, be sure to visit the Beneath the Surface video blog on Healio.com. 

Disclosures: Gelfand reports no relevant financial disclosures. King reports having financial relationships with AbbVie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Arena Pharmaceuticals, Aslan Pharmaceuticals, BiologicsMD, Bristol Meyers Squibb, Concert Pharmaceuticals, Eli Lilly, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka/Visterra, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, TWi Biotechnology and Ventyx Biosciences.